Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase i trial with an extensive biomarker program
Markus Moehler*, Annett Maderer, Anne Ehrlich, Friedrich Foerster, Arno Schad, Tanja Nickolay, Christian Ruckes, Arndt Weinmann, Visvakanth Sivanathan, Jens U. Marquardt, Peter Robert Galle, Marcus Woerns, Thomas Thomaidis
Untersuchen Sie die Forschungsthemen von „Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, phase i trial with an extensive biomarker program“. Zusammen bilden sie einen einzigartigen Fingerprint.